Andrés Matesanz, general manager at DCS Pharma Mexico, explains how the merger between Dolder and Chemswiss has enlarged the capabilities and the offering of the company in Mexico and showcases the added value of DCS Pharma being considered the fastest option within the industry.
ChemSwiss has recently merged with Dolder. Could you explain to our international readers how it has been perceived by your clients and how your operations have been affected since then?
"This year, as we are still under the business consolidation process with Dolder, we expect to grow around 35 percent in 2016, but the potential ahead is way bigger."
Tags:
